ArticleFrontiers in medicine2026
A scalable and reliable deep learning framework for enhanced brain tumor detection and diagnosis using AI-based medical imaging.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brain Tumor Segmentation and Grading on MRI Using Deep Learning: A Systematic Literature Review and Benchmark-Driven Comparative Analysis.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The proposed Architecture will provide the processing and analysis essential to accurate and reliable detection of brain tumors from MRI, for timely diagnosis and evidence-based decisions. Medical imaging now routinely enters clinical assessment; the thrust is shifting toward attaining high performance within open and governed systems to enable deployment in real-world healthcare applications. Methods: This paper proposes a two-stage deep learning framework: first, DeepLabV3 for segmentation to demarcate candidate tumor regions, and then CNN to classify whether a tumor exists. The different components employ pre-trained models through transfer learning and fine-tuning. The DeepLabV3 and CNN architectures are used, together with metric computation modules. This approach will be tested on BraTS MRI data. For efficient model training, optimizers such as SGD, RMSprop, and Adam can be employed. Results: The classification performance could be achieved with a high value of 99.31% using an ADAM optimizer in the proposed architecture. Besides, both the precision and recall are very high, indicating good generalization and stable performance. Moreover, segmenting before classification provides more reliable detection compared to using a single-stage model. Discussion: These results indicate that feature learning guided by segmentation enhances tumor detection with a binary classifier, while remaining interpretable and robust. This makes the framework much more transparent and easy to audit, suitable for use in cloud-enabled, secure, and IoT-enabled clinical environments. Originality: It therefore proposes a two-layer deep learning architecture that effectively incorporates precise tumor localization into explicit binary tumor detection. Beyond this, the work focuses on practical clinical applicability, robust data governance, and deployment-ready systems rather than diagnosing subtypes of tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.